Neuroimmunology Drug Development Summit – What You Could Have Expected in 2024?
Neuroimmunology discovery has continued to expand over the past year, with emerging and continued biology and target investigation against TREM2, RIPK1, ferroptosis, NLRP3, LRRK2, and beyond. However, there are still significant translational barriers to overcome to see clinical success of neuroinflammatory modulators and tackle the huge unmet patient need in neurology.
Characterizing and harnessing functions and interactions of microglia, astrocytes, oligodendrocytes, and infiltrating adaptive immune cells are key to discovering and developing therapies to treat underlying neuroinflammation in Alzheimer’s, Parkinson’s, multiple sclerosis, and beyond.
Attendees joined 100+ biopharma experts from Alector, Lundbeck, Vigil Neuroscience, Biogen, BMS, Muna Therapeutics, Pipeline Therapeutics, PTC Therapeutics, and more, to break down novel glial biology and neuroinflammatory target investigation, adapt immunity contributions, state of the art microglial iPSCs, humanized rodent models, neuroinflammatory biomarkers, and early clinical learnings to optimize neuroimmunology translation and develop transformative therapeutics for neurological disorders.
2024 Agenda Highlights Included:
Hear new clinical updates from ongoing trials for Alzheimer’s Disease and multiple sclerosis, detailing clinical data, trial design rationale, patient stratification, and TREM2 target engagement with Alector, Vigil Neuroscience, and Pipeline Therapeutics
Discover immunocompetent brain organoid and 3D culture development to recapitulate and investigate complex in vitro neuroinflammatory environments with Herophilus and Roche
Deep dive into neuroinflammatory biomarkers against TREM2 and other neuroinflammatory targets to stay up-to-date with biomarker discovery, and validation with clinical outcomes with Lundbeck and Merck
Explore increased representation on cutting-edge functional understanding and therapeutic development against reactive astrocytes with Sanofi, UCL, and IMNEWRUN
Discuss and debate in vitro and in vivo preclinical model complexity, limitations, and reverse translation case studies to optimize successful translation neuroinflammatory-targeted therapeutics into clinical trials with Eisai, Regeneron, and EMD Serono
Who could you meet in 2025?
As the leading industry meeting for the neuroimmunology drug development community, this summit is the best opportunity to enjoy face-to-face interactions with past peers and new connections to create and strengthen novel relationships to shape the future of neuroinflammatory-targeted therapeutics.
